Reason for CPXcitement in AML

Joshua F. Zeidner, Judith E. Karp

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


In this issue of Blood, Lancet et al report their findings that CPX-351, a liposomal formulation of cytarabine and daunorubicin in a 5:1 molar ratio, produces superior response rates compared with 713 in older patients with acute myeloid leukemia (AML).

Original languageEnglish (US)
Pages (from-to)3211-3212
Number of pages2
Issue number21
StatePublished - May 22 2014

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Reason for CPXcitement in AML'. Together they form a unique fingerprint.

Cite this